Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Esperion (NASDAQ: ESPR) today and set a price target of $82. The company’s shares opened today at $40.77, close to its 52-week low of $33.06.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 1.3% and a 36.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and United Therapeutics.
Esperion has an analyst consensus of Strong Buy, with a price target consensus of $82, which is a 101.1% upside from current levels. In a report issued on October 16, BTIG also initiated coverage with a Buy rating on the stock with a $82 price target.
.
See today’s analyst top recommended stocks >>
Based on Esperion’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $45.73 million. In comparison, last year the company had a GAAP net loss of $45.22 million.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ESPR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
